One-third of the B400 nonodorant G protein-coupled receptors (GPCRs) are still orphans. Although a considerable number of these receptors are likely to transduce cellular signals in response to ligands that remain to be identified, they may also have ligand-independent functions. Several members of the GPCR family have been shown to modulate the function of other receptors through heterodimerization. We show that GPR50, an orphan GPCR, heterodimerizes constitutively and specifically with MT 1 and MT 2 melatonin receptors, using biochemical and biophysical approaches in intact cells. Whereas the association between GPR50 and MT 2 did not modify MT 2 function, GPR50 abolished high-affinity agonist binding and G protein coupling to the MT 1 protomer engaged in the heterodimer. Deletion of the large C-terminal tail of GPR50 suppressed the inhibitory effect of GPR50 on MT 1 without affecting heterodimerization, indicating that this domain regulates the interaction of regulatory proteins to MT 1 . Pairing orphan GPCRs to potential heterodimerization partners might be of clinical importance and may become a general strategy to better understand the function of orphan GPCRs.
Introduction
Although the formation of functional protein complexes via dimerization or oligomerization is a common theme in biology, G protein-coupled receptors (GPCRs) were assumed to exist as monomers for many years since the heterologous expression of a single GPCR was usually sufficient to produce the expected pharmacology and function. However, biochemical and structural data accumulated over the last 15 years indicate that most, if not all, GPCRs exist as functional dimers or higher oligomeric units (Bouvier, 2001; Milligan, 2004) . GPCR dimerization includes the formation of homodimers (between two identical receptor protomers) and heterodimers (between two protomers of different receptors). GPCR heterodimerization has been reported for more than 40 receptor combinations (Prinster et al, 2005) and in most of these cases heterodimerization had a marked effect on GPCR function. Some GPCRs function as obligatory heterodimers as shown for the GABA B and taste (T1R 1À3 ) receptors. Other GPCRs may form heterodimers allowing for mutual regulation (trafficking, desensitization) between the two specific promoters within the heterodimer as observed in most of the known cases. Finally, heterodimerization may profoundly modify the pharmacological properties of the receptor.
Recent genome sequencing projects indicated that approximately 370 sequences belong to the nonodorant GPCR family in the human genome (Joost and Methner, 2002; Fredriksson et al, 2003; Vassilatis et al, 2003) . More than 220 of these receptors have been matched with known ligands. However, over 140 receptors (E40%) still remain as orphans despite the vast and long-standing effort of academic and industrial research to pair these receptors to potential ligands (Vassilatis et al, 2003) .
Whereas a considerable amount of data has been accumulated on the homo-and heterodimerization of GPCRs with known ligands, nothing is known about the dimerization of orphan receptors. Heterodimerization between orphan and nonorphan GPCRs opens the interesting possibility that orphan receptors regulate the ligand binding, signaling and/or trafficking of GPCRs with known ligands.
We specifically addressed this issue by studying the dimerization of the orphan X-linked GPR50 receptor whose function is unknown (Reppert et al, 1996; Drew et al, 1998; Drew et al, 2001) . A deletion mutant of GPR50 has been recently shown to be genetically associated with mental diseases such as bipolar affective disorder and major depressive disorder (Thomson et al, 2005) . Moreover, some GPR50 variants are associated with higher triglyceride levels and lower HDL-cholesterol levels (Bhattacharyya et al, 2006) . We show that GPR50 homodimerizes and forms heterodimers with MT 1 and MT 2 melatonin receptors that share the highest sequence homology with GPR50 among all GPCRs. Importantly, MT 1 loses its ability to bind to melatonin receptorspecific agonists and to couple to G proteins when engaged into GPR50/MT 1 heterodimers. Our results shed light on a previously unappreciated role of orphan receptors in the regulation of nonorphan GPCRs with known function.
Results

Homo-and heterodimerisation of GPR50
The formation of GPR50 homodimers was first explored in Western blot experiments. In HEK 293 cell extracts expressing a fusion protein between GPR50 and the yellow fluorescent protein (YFP) (GPR50-YFP), anti-GFP antibodies detected two immunoreactive species with apparent molecular weights of approximately 90 and 180 kDa, likely corresponding to the monomeric and dimeric form of GPR50-YFP ( Figure 1A ). To confirm GPR50 homodimerization, we performed co-immunoprecipitation experiments with differentially tagged receptors. When immunoprecipitating GPR50-YFP, co-precipitated Flag-GPR50 was revealed in SDS-PAGE as a monomer at 70 kDa and as a SDS-resistant dimer at 140 kDa ( Figure 1B) . GPR50 belongs to the melatonin receptor GPCR subfamily that in humans comprises two further subtypes, MT 1 and MT 2 (Reppert et al, 1996) . To explore GPR50 heterodimerization with MT 1 and MT 2 , GPR50-YFP was coexpressed with the N-terminally Flag-tagged MT 1 and Myc-tagged MT 2 . Anti-GFP antibodies were indeed able to specifically pull down MT 1 and MT 2 proteins (Figure 1C and D) . Formation of MT 1 /GPR50 heterodimers was further supported by direct Western blot experiments (see Supplementary Figure 1 ). Taken together, Western blot and co-immunoprecipitation experiments suggest that GPR50 form homo-and heterodimers.
To exclude possible artefacts associated with coimmunoprecipitation of membrane-bound receptors solubilized in detergent, we studied GPR50 dimerization in intact cells using the Bioluminescence Resonance Energy Transfer (BRET) approach. The GPR50-Rluc construct was used as BRET donor and was coexpressed with the BRET acceptor YFP fused to the C-terminus of different receptors (Figure 2A ). Significant energy transfer was observed in cells coexpressing GPR50-Rluc with similar amounts of GPR50-YFP, MT 1 -YFP or MT 2 -YFP. These BRET signals were comparable to those obtained for the MT 1 homodimer expressed at similar levels. Stimulation of cells with melatonin did not modify the basal BRET signals (not shown). The specificity of the assay was illustrated by the absence of significant transfer between GPR50-Rluc and YFP fusion proteins of control GPCRs (b 2 -adrenergic receptor (b 2 -AR) and CCR5) expressed in similar amounts to those of melatonin receptor YFP fusions. Taken together, BRET experiments show that GPR50 is engaged into constitutive homo-and heterodimeric complexes with MT 1 and MT 2 in intact cells.
The relative propensity of GPR50 to form homodimers or to engage into heterodimers with MT 1 or MT 2 was then studied with the recently developed BRET donor saturation assay (Mercier et al, 2002; Couturier and Jockers, 2003; Ramsay et al, 2004) . Cells were cotransfected with constant amounts of the BRET donor (receptor fused to Rluc) and increasing quantities of the BRET acceptor (receptor fused to YFP). In this assay, the amount of acceptor required to obtain the half-maximal BRET (BRET 50 ) for a given amount of donor reflects the relative affinity of the two partners (Mercier et al, 2002) . Specific BRET signals increased as a hyperbolic function and reached an asymptote with increasing acceptor/ donor ratios. Comparable BRET 50 values of 0.3670.08, 0.3570.08 and 0.4170.06 (n ¼ 3-5) were obtained for GPR50 homodimers, GPR50/MT 1 heterodimers and GPR50/ MT 2 heterodimers, respectively ( Figure 2B-D) , indicating that the propensity of GPR50 heterodimerization with MT 1 and MT 2 is similar to that of GPR50 homodimerization. For control receptors (b 2 -AR and CCR5), BRET signals increased linearly and were not saturable as expected for nonspecific interactions.
Consequences of GPR50 heterodimerization on ligand binding to MT 1 and MT 2
To assess the functional consequences of GPR50 heterodimerization with MT 1 and MT 2 , we generated a HEK 293 cell line stably expressing the GPR50-YFP fusion protein (HEK-GPR50). Incubation of these cells with a saturating concentration of 2( 125 I)-iodomelatonin ( 125 I-MLT) for MT 1 and MT 2 confirmed that GPR50 has no apparent affinity for this radioligand as previously reported (Reppert et al, 1996) ( Figure 3A ). The effect of GPR50 on 125 I-MLT binding to MT 1 and MT 2 was studied by expressing MT 1 -Rluc and MT 2 -Rluc fusion proteins in HEK-GPR50 cells and wild-type HEK 293 cells (HEK-wt). Despite the presence of similar quantities of MT 1 -Rluc in both cell lines, as determined by luminescence measurements, the number of 125 I-MLT-binding sites was decreased by more than 50% in HEK-GPR50 cells ( Figure 3A ). No such effect was observed when comparable quantities of MT 2 -Rluc were expressed ( Figure 3B ). Hence, GPR50 specifically decreases 125 I-MLT binding to MT 1 but not to MT 2 . In addition, decreased 125 I-MLT binding is unlikely to Figure 3C ). The decreased binding effect was dependent on the GPR50 concentration as expression of increasing amounts of GPR50-YFP progressively decreased the amount of 125 I-MLT-binding sites ( Figure 3D ). The amount of surface-expressed Flag-MT 1 in this stable cell clone remained unchanged by GPR50-YFP coexpression when monitored by flow cytometry using an antibody directed against the Flag epitope.
Dimerization between MT 1 and its known heterodimerization partner MT 2 (Ayoub et al, 2002) was used to assess the specificity of the inhibitory effect of GPR50 on 125 I-MLT binding to MT 1 . In cells expressing Flag-MT 1 and MT 2 -YFP, the number of 125 I-MLT-binding sites was higher than in cells expressing the same amount of Flag-MT 1 alone, consistent with the fact that the radioligand may bind both MT 1 and MT 2 ( Figure 3C ). Moreover, an MT 2 -C113A-YFP mutant, which has lost the capacity of 125 I-MLT binding (Mseeh et al, 2002) , still heterodimerized with MT 1 (Supplementary Figure  2) without blocking 125 I-MLT binding of the MT 1 protomer ( Figure 3C ). This suggests that 125 I-MLT binding to MT 1 is not modified in the MT 1 /MT 2 heterodimer. Accordingly, the inhibitory effect of GPR50 on 125 I-MLT binding to MT 1 appears to be specific for the GPR50/MT 1 heterodimer.
We next performed 125 I-MLT saturation experiments to determine the precise impact of GPR50 on the B max and K d of 125 I-MLT binding to MT 1 ( Figure 3E ). The 125 I-MLT saturation curves were best fitted using a nonlinear regression equation with a single binding site indicating the presence of a single pharmacological species. Comparable K d values of 290764 pM and 335756 (n ¼ 3) were obtained in cells expressing MT 1 -Rluc in the presence and absence of GPR50-YFP, respectively. B max values decreased to 5179.4% in the presence of GPR50-YFP. The pharmacological profile of MT 1 was then determined in the presence and absence of GPR50 in 125 I-MLT competition binding experiments. In cells expressing MT 1 alone, the K i values obtained for six melatonin receptor-specific ligands were in accordance with previously reported values (Dubocovich et al, 1997; Audinot et al, 2003; Ayoub et al, 2004) (Table I) . Very similar K i values were obtained for the remaining 125 I-MLT-binding sites in the presence of GPR50. Our data suggest that the 125 I-MLTbinding sites observed in the presence of GPR50 most likely correspond to MT 1 homodimers, whereas MT 1 /GPR50 heterodimers are unable to bind 125 I-MLT. To further confirm this hypothesis, MT 1 homodimers and MT 1 /GPR50 heterodimers were separated by selective co-immunoprecipitation and 125 I-MLT binding of the different receptor pairs was determined. MT 1 -YFP or GPR50-YFP were coexpressed with Flag-MT 1 , labeled with a saturating 125 I-MLT concentration, solubilized and adjusted to similar YFP fluorescence values. Previous studies have shown that 125 I-MLT remains stably bound to MT 1 under these experimental conditions (Brydon et al, 1999) . Whereas anti-GFP-specific antibodies readily precipitated 12% of the Western blot experiments performed with the same samples confirmed that equivalent quantities of Flag-MT 1 were co-immunoprecipitated from both samples. As expected, no radioactivity was precipitated in control experiments from cells expressing the Flag-MT 1 (À) or GPR50-YFP constructs individually, thus illustrating the specificity of the assay. Our results confirm the hypothesis that MT 1 loses its ability to bind to 125 I-MLT when engaged into the GPR50/MT 1 heterodimer.
GPR50 antagonizes MT 1 signaling
To verify whether GPR50 interferes also with melatoninpromoted MT 1 signaling, coupling of MT 1 to the G i protein was assessed in the absence and presence of GPR50-YFP. A previously described G ai/q chimera that couples G i -coupled receptors to phospholipase C activation was used as a functional read-out for MT 1 activation (Goudet et al, 2004 ). The natural hormone melatonin and the synthetic melatonin receptor-specific agonist S20098 dose-dependently increased the functional response with EC 50 values of 57.773.5 and 37.073.8 pM respectively, in agreement with published values (Godson and Reppert, 1997; Petit et al, 1999) ( Figure 5A and B). Coexpression of GPR50-YFP had no major effect on the basal value and the EC 50 values (39.672.1 and 9.373 pM for melatonin and S20098, respectively), but decreased the maximal response by 50 and 45% for melatonin and S20098, respectively. This decrease of the maximal response was not due to decreased expression levels of MT 1 -Rluc when coexpressed with GPR50-YFP as monitored by measuring the luminescence of the Rluc fusion protein ( Figure 5A inset) . These results show that GPR50 antagonizes the functional response of the MT 1 receptor when stimulated by the synthetic S20098 compound and importantly the natural hormone, melatonin.
Effect of GPR50 downregulation on MT 1 function in hCMEC/D3 cells expressing endogenous receptors
The fact that melatonin is known to regulate cerebral blood flow (Regrigny et al, 1998; Yang et al, 2001) and that melatonin receptors are expressed in the vascular system (Savaskan et al, 2001 ) prompted us to search for the expression of endogenous melatonin receptors in recently immortalized human endothelial cerebral hCMEC/D3 cells (Weksler et al, 2005) . RT-PCR experiments revealed the coexpression of MT 1 and GPR50 transcripts ( Figure 6A ). GPR50-selective siRNA duplexes were synthesized to investigate the effect of GPR50 downregulation on MT 1 function. The most efficient siRNA decreased the expression of GPR50-YFP in the HEK-GPR50 cells by 80% as monitored by flow cytometry ( Figure 6B ). Transfection of the GPR50-siRNA in hCMEC/D3 cells decreased the expression of the GPR50 transcript by 60%, whereas an Alexa Fluor 488-labeled control siRNA was without significant effect ( Figure 6C ). The effect of GPR50 downregulation was tested on 125 I-MLT binding. Whereas specific 125 I-MLT binding was hardly detectable in nontransfected and in control-siRNA-transfected cells, significant binding was consistently observed in GPR50-siRNA-treated cells ( Figure 6D ). In agreement with these observations, melatonin and S20098 inhibited forskolinpromoted cAMP accumulation only in GPR50-siRNA-treated cells ( Figure 6E ). The results obtained in hCMEC/D3 cells expressing both receptors endogenously further support the physiological significance of the inhibitory effect of GPR50 on MT 1 function.
Mechanism of the antagonistic effect of GPR50 on MT 1 function
The decreased responsiveness of MT 1 in the presence of GPR50 could be explained by an alteration in the steadystate cell-surface expression of MT 1 owing to a change in receptor trafficking as demonstrated for other GPCR heterodimers (Jordan et al, 2001) . However, it is not observed for MT 1 /GPR50 heterodimers, as Flag-MT 1 was expressed at the cell surface irrespective of the coexpression or absence of GPR50-YFP, as quantified in a cell surface ELISA ( Figure 7F ) and visualized by fluorescence microscopy ( Figure 7A and C). GPR50-YFP itself localized to the cell membrane (Figure 7F ), whereas GPR50-YFP remained at the cell surface ( Figure 7G ). Taken together, these data suggest that MT 1 homodimers are internalized upon melatonin stimulation conversely to GPR50 homodimers and MT 1 /GPR50 heterodimers.
Intriguingly, GPR50 displays a noncanonical C-terminal tail of 311 residues (Reppert et al, 1996) . To study the potential role of the C-terminus on 125 I-MLT binding to the MT 1 /GPR50 heterodimer, 264 amino acids of the intracellular domain were deleted. The first 55 amino acids of the C-terminus were conserved in the GPR50DCter mutant to maintain potentially important structural elements such as the eighth alpha-helical domain located at the membraneproximal part of the C-terminus. In contrast to the full-length GPR50-YFP, expression of GPR50DCter-YFP or the C-terminus of GPR50 alone in cells stably expressing Flag-MT 1 failed to decrease 125 I-MLT binding in a context where MT 1 surface expression was not affected ( Figure 8A ). Immunofluorescence experiments showed that the GPR50DCter-YFP mutant localized exclusively at the cell surface similarly to the full-length receptor, thus excluding a defect in receptor trafficking (not shown). In agreement with the results obtained in 125 I-MLT-binding experiments ( Figure 8B ), signaling of MT 1 was affected in the presence of GPR50-YFP but was not impaired by equivalent expression levels of GPR50DCter-YFP ( Figure 8B ). BRET experiments using the GPR50DCter-Rluc fusion protein as BRET donor showed that the dimerization pattern of the mutant was identical to that of the full-length receptor ( Figure 8C ). Specific BRET signals were observed for GPR50DCter/GPR50, GPR50DCter/MT 1 and GPR50DCter/MT 2 dimers but not with the b 2 -AR. Consequently, the effect of GPR50 on MT 1 function clearly depends on the presence of the large C-terminal tail in the full-length GPR50.
A possible mechanism of the inhibitory effect of GPR50 on MT 1 function is to hinder recruitment of intracellular interacting partners to MT 1 such as G i proteins. Impaired G i recruitment to MT 1 may also explain the loss of binding of the radiolabeled melatonin receptor agonist 125 I-MLT to MT 1 in the MT 1 /GPR50 heterodimer, as high-affinity agonist binding to MT 1 depends on the presence of G i (Barrett et al, 1994; Drew et al, 1997) . To verify this hypothesis, MT 1 -YFP or GPR50-YFP was expressed alone or with Rluc fusion proteins of GPR50, GPR50DCter or MT 1 as indicated in Figure 9A . Cell lysates containing equivalent quantities of YFP fusion proteins were immunoprecipitated and the presence of G ia was revealed by Western blotting. G ia was readily co-precipitated from melatonin-stimulated MT 1 -YFP-containing cell lysates ( Figure 9A , lane 1) confirming previous observations (Brydon et al, 1999) . The specificity of the assay was illustrated by the absence of G ia immunoreactivity in precipitates prepared from nontransfected cells ( Figure 9A, lane 7) . G ia was also observed in co-immunoprecipitates from GPR50-YFP-and GPR50DCter-YFP-containing cell lysates ( Figure 9A , lanes 2 and 3). At comparable receptor levels, the amount of G ia associated with GPR50-YFP was lower compared to MT 1 -YFP lysates and even lower for GPR50DCter-YFP. Identical amounts of G ia were precipitated in the absence of melatonin stimulation (not shown). This indicates a certain degree of G i preassociation to GPR50 (lane 2), which could depend on the C-terminus of GPR50 (lane 3). Preassociation of G proteins has also been observed recently for other GPCRs in intact cells (Bunemann et al, 2003; Gales et al, 2005) . When MT 1 was coexpressed with GPR50 (lanes 4 and 6), less G ia was co-precipitated compared to cell lysates prepared from cells expressing MT 1 -YFP alone at comparable receptor levels (compare lanes 1 and 4). This observation suggests that the Cter of GPR50 impedes G ia recruitment to MT 1 in the MT 1 /GPR50 heterodimer. Indeed, the amount of co-precipitated G ia clearly increased when MT 1 -YFP was coexpressed with the GPR50DCter-Rluc construct (similar quantity as for the full-length GPR50-Rluc) (lanes 4 and 5), confirming that recruitment of G ia to MT 1 is maintained only in the absence of the GPR50 Cter. Neither G qa , G sa nor G 12a was found in GPR50/MT 1 precipitates (Supplementary Figure  3, lane 4) , indicating that the GPR50/MT 1 heterodimer is completely devoid of G protein coupling.
Whether such a mechanism extends to other GPCR interacting partners such as b-arrestin was studied in a BRETbased b-arrestin recruitment assay. Dynamic recruitment of b-arrestin 1 to MT 1 was observed upon melatonin stimulation of cells coexpressing MT 1 -Rluc and an N-terminally YFPtagged b-arrestin 1 fusion protein ( Figure 9B) . A plateau was reached after approximately 15 min, which is consistent with reported b-arrestin recruitment kinetics. Coexpression of Flag-GPR50 decreased the melatonin-induced BRET signal ( Figure 9C , black bars) without modifying the expression levels of the two BRET partners (not shown). This result is consistent with a decrease of melatonin-sensitive MT 1 homodimers when coexpressed with GPR50 and an increase of melatonin-insensitive GPR50/MT 1 heterodimers. Interestingly, coexpression of GRP50 increased at the same time the basal BRET level ( Figure 9C , white bars), suggesting a constitutive interaction between b-arrestin and the GPR50/MT 1 heterodimer. Collectively, our data show that MT 1 is devoid of G protein coupling in the presence of GPR50, a phenomenon that might depend on the presence of the long C-terminal tail of GPR50 and on the constitutive interaction of the GPR50/MT 1 heterodimer with b-arrestins.
Discussion
It has become widely accepted that many members of the nonodorant GPCRs have the capacity to homo-and heterodimerize with important functional consequences on receptor pharmacology, signaling and regulation. So far, this has only been studied for GPCRs with known ligand and function. We are now extending the idea of GPCR dimerization towards orphan GPCRs. Using a combination of biochemical and biophysical techniques we show that the orphan GPR50 follows the general pattern of GPCR dimerization established for GPCRs with known ligands: GPR50 exists as constitutive homodimer or oligomer and heterodimerizes with other GPCRs in a specific manner (association with MT 1 and MT 2 but not with b2-AR and CCR5) with similar propensities for homo-and heterodimer formation. Importantly, engagement of the orphan GPR50 into heterodimers with MT 1 , known to bind the circadian neurohormone melatonin, had profound consequences on MT 1 function. This effect appears to be specific for the GPR50/MT 1 heterodimer since it was not observed for heterodimers with the closely related MT 2 .
Inhibition of GPCR function through heterodimerization has been observed for other GPCRs such as for the angiotensin II AT 1 receptor whose function is antagonized in AT 1 /AT 2 and AT 1 /Mas heterodimers (AbdAlla et al, 2001; Kostenis et al, 2005) . In the case of the AT 1 /AT 2 heterodimer, it has been suggested that the AT 2 receptor, which lacks common features of G protein coupling, stabilizes a conformation of the AT 1 receptor that can no longer undergo the conformational change necessary for G protein coupling. For the AT 1 /Mas heterodimer, the molecular mechanism of antagonism has not been clarified yet. In the present report, we establish a novel mechanism for the inhibition of GPCR function by heterodimerization, through inhibition of the recruitment of intracellular interacting partners such as G proteins owing to sterical hindrance by the large C-terminal domain of GPR50. b-Arrestin which could be constitutively recruited to the heterodimer might also contribute to the impaired G protein coupling of the heterodimer since both proteins have overlapping interaction sites with the receptor. Whether the constitutive interaction of b-arrestin with the GPR50/MT 1 heterodimer induces b-arrestin-dependent signaling events remains to be clarified in future studies.
The GPR50 mRNA is widely expressed in the brain with preferential expression in the hypothalamic-pituitary-adrenocortical system (Reppert et al, 1996; Drew et al, 1998 Drew et al, , 2001 Vassilatis et al, 2003) where overlapping expression patterns with MT 1 and MT 2 have been observed. This point is further supported by our studies in human endothelial cerebral hCMEC/D3 cells.
Inhibition of MT 1 function by heterodimerization with GPR50 raises the question of the regulation of this process. Our data showed that the relative propensity of GPR50/MT 1 heterodimer formation compared to GPR50 homodimers depends on the relative expression levels of both receptors when coexpressed in the same cells. Coexpression of receptors such as the MT 2 that heterodimerize with GPR50 without any obvious functional consequences may behave as a competitor of the GPR50/MT 1 heterodimer. Little is known about the expression profile of GPR50 but differential regulation during development or during the day-night cycle can be postulated as shown for MT 1 (Poirel et al, 2002; Danilova et al, 2004) . Regulation of GPR50 mRNA levels by microRNA molecules is also likely since expression of an miRNA sequence specifically targeting the 3 0 untranslated region of the GPR50 transcript has been shown in the brain including the hypothalamic-pituitary-adrenocortical system (John et al, 2004; Sempere et al, 2004) .
Several features of GPR50 suggest that orphan GPCRs may have important functions even in the absence of any known ligand binding properties. GPR50 was originally cloned from human pituitary cDNA library using degenerated PCR primers based on MT 1 and MT 2 (Reppert et al, 1996) . The high degree of sequence homology with MT 1 and MT 2 , the presence of shared amino-acid motifs and the conservation of the overall gene structure clearly confirmed the classification of GPR50 in the melatonin receptor subfamily. Despite intensive efforts to deorphanize GPR50 with the latest state of the art GPCR ligand screening technology, the ligand of GPR50 remains elusive, even 9 years after its cloning and classification. Unusual features of GPR50 that may hint at important ligand-independent functions include the long C-terminus that is more than 300 amino acids long. It is likely that the C-terminus may either inhibit protein recruitment as shown in the GPR50/MT 1 heterodimer or function as a protein scaffold for other intracellular proteins. The recently discovered insertion/deletion polymorphism genetically associated with psychiatric disorders is located in the C-terminus underlining the functional importance of this domain.
Our finding raises the interesting possibility that some orphan GPCRs are not capable of binding any endogenous ligand but rather regulate the function of non-orphan GPCRs through heterodimerization or other mechanisms. Although this hypothesis is obviously difficult to prove, several recent observations are in favor of such mechanisms. The recent completion of the human genome allowed a comprehensive classification of GPCRs. In total, 12 human and 49 mice orphan GPCRs were assigned to subfamilies with known ligands (Vassilatis et al, 2003) . Two further studies analyzing either sequences of the human rhodopsin GPCR subfamily or comparing human and drosophila GPCRs came to a similar conclusion (Fredriksson and Schioth, 2005; Metpally and Sowdhamini, 2005) . Despite the fact that a good prediction for the putative ligand could be made, most of the receptors still remain as orphans (Civelli, 2005) consistent with the hypothesis that some receptors are unable to bind any ligand.
Additional support for the potential functional significance of heterodimers between orphan and nonorphan GPCRs comes from obligatory heterodimers observed in other GPCR classes. The functional GABA B receptor is composed of two homologous subunits called GABA B1 and GABA B2 . Interestingly, each subunit of this obligatory heterodimer has a distinct function, whereas GABA B1 provides ligand binding, GABA B2 promotes efficient trafficking of GABA B1 to the cell surface (White et al, 1998) . Mechanistically, GABA B2 can thus be considered as an 'orphan' receptor in the heterodimer. T1R 1 /T1R 3 and T1R 2 /T1R 3 heterodimers of taste receptors appear also to function as heterodimers between orphan and nonorphan receptors. T1R 1 and T1R 2 , originally discovered as orphan receptors, have subsequently been 'deorphenized' by the discovery of their heterodimerization partner T1R 3 . According to the current working model, taste receptor heterodimers are composed of T1R 1 and T1R 2 , which bind the ligand, and the orphan T1R 3 (Xu et al, 2004) . Similar observations have been made for the insect odorant receptor DOR83b that has no apparent affinity for a large panel of odorants but strongly increases the functionality of other odorant receptors such as DOR43 by heterodimerization (Neuhaus et al, 2005) . (B) Cells were stimulated for 30 min with 1 mM forskolin alone (black bars) or in the presence of 1 mM melatonin (white bars) or 1 mM S20098 (hatched bars) and cAMP levels were determined (**Po0.01; NS, P40.05 compared with corresponding NT condition). (C) GPR50DCter-Rluc was transiently coexpressed in HEK 293 cells with the indicated C-terminal YFP fusion proteins expressed at comparable amounts as determined by direct fluorescence measurements (20-30 fmol of YFP fusion receptor per mg of protein as estimated from curves correlating YFP fluorescence with the number of 125 I-MLT-binding sites (Ayoub et al, 2002) ). BRET measurements were performed in living cells by adding 5 mM coelenterazine. All data are means7s.e.m. of at least three independent experiments each performed in duplicate. NT, nontransfected. In conclusion, the orphan GPR50 antagonizes the function of MT 1 , which constitutes the first example of functional heterodimer formation between an orphan GPCR and a member of the large rhodopsin-like GPCR family with a known ligand. We propose that some orphan GPCRs could have ligand-independent functions such as the regulation of other GPCRs through heterodimerization. In this respect, evolutionary conservation of orphan receptors without any ligand binding may be considered as an evidence for the physiological importance of GPCR heterodimerization.
GPRΔCter-Rluc
Studying the heterodimerization profile of orphan GPCRs may become a new strategy to obtain better insights in the biology of GPCRs with known ligands and functions. (Ayoub et al, 2002) , b 2 -AR-YFP (Angers et al, 2000) , CCR5-YFP (Issafras et al, 2002) and YFP-b-arrestin-1 (Storez et al, 2005) have been described elsewhere. All GPR50 constructs were obtained by PCR using the described N-terminally Flag-tagged human GPR50 construct (Conway et al, 2000) . GPR50DCter constructs are composed of GPR50 amino acids 1-349 and the Cter construct contains the amino acids 307-613.
Materials and methods
Chemicals and reagents
Cell culture, transfection and RNA interference HEK 293 cells were grown and transfected as described (Ayoub et al, 2002) . Human endothelial cerebral hCMEC/D3 cells were cultured as described (Weksler et al, 2005) . GPR50-specific siRNA duplexes are available upon request.
Reverse transcription-polymerase chain reaction
Total RNA was isolated using the TRIZOL Reagent (Invitrogen) as described by the manufacturer. PCR primers and conditions are available upon request.
Determination of intracellular inositol phosphates and cAMP levels
Inositol phosphate accumulation was performed in 96-well microplates after cell labeling overnight with [ 3 H]myo-inositol, 0.5 mCi/ well (Amersham Biosciences) in the medium as described previously (Goudet et al, 2004) . Cyclic AMP levels were determined by HTRF using the Cisbio 'cAMP femto2' kit according to the manufacturer's instructions. I-MLT radioligand binding assays were performed as described previously (Ayoub et al, 2002) . IC 50 values were transformed into K i values using the Cheng-Prussof formula:
Binding assays
Immunoprecipitation and Western blotting Co-immunoprecipitation: Crude membranes were solubilized with 1% digitonin and immunoprecipitated with the monoclonal anti-GFP antibody (4 mg/ml) (Roche, Basel, Switzerland) as described previously (Ayoub et al, 2004) . G protein immunoprecipitation were carried out as described by Brydon et al (1999) using monoclonal anti-GFP (4 mg/ml) and polyclonal anti-G ai3 C-10 (0.4 mg/ml) (Santa Cruz, CA) antibodies.
BRET assay, luminescence and fluorescence measurements BRET experiments, luminescence and fluorescence measurements were performed as described (Ayoub et al, 2002 (Ayoub et al, , 2004 .
Immunofluorescence microscopy and cell surface ELISA Fixed cells were permeabilized by 0.2% Triton X-100 first incubated with monoclonal anti-Flag antibody (Sigma, St Louis, MO) (2 mg/ ml) and subsequently with a Cy3-coupled secondary antibody. For detecting GFP and Cy3 fluorescence, samples were excited using an argon laser at a wavelength of 488 nm for GFP and 514 nm for Cy3. Cell surface ELISA were performed as described (Brydon et al, 1999) using anti-Flag M2 (3 mg/ml) antibodies.
Supplementary data
Supplementary data are available at The EMBO Journal Online. 
